ESPR (Esperion Therapeutics, Inc.) Stock Financials & Earnings

ESPREsperion Therapeutics, Inc.

Mkt Cap$577M

Revenue (TTM)$304M

Net Income (TTM)-$106M

EPS (TTM)-$0.50

Free Cash Flow (TTM)-$93M

Gross Margin53.5%

Op. Margin-9.7%

Net Margin-34.8%

FCF Margin-30.7%

P/S Ratio (TTM)1.9x

P/E Ratio (TTM)—

YoY Rev Growth+2.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$19M	$15M	-$43M
Q1 23	$24M	$13M	-$49M
Q2 23	$26M	$19M	-$37M
Q3 23	$34M	$21M	-$28M
Q4 23	$32M	$21M	-$42M
Q1 24	$138M	$128M	$72M
Q2 24	$74M	$58M	$3M
Q3 24	$52M	$34M	-$16M
Q4 24	$69M	$43M	-$4M
Q1 25	$65M	$33M	-$22M
Q2 25	$82M	$54M	$7M
Q3 25	$87M	$32M	-$10M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 22	$33M	—	—	$24M
Q1 23	$31M	—	—	$30M
Q2 23	$22M	—	—	$34M
Q3 23	$15M	—	—	$33M
Q4 23	$18M	—	—	$45M
Q1 24	$13M	—	—	$42M
Q2 24	$11M	—	—	$44M
Q3 24	$10M	—	—	$40M
Q4 24	$11M	$11M	$26M	—
Q1 25	$13M	—	—	$43M
Q2 25	$7M	—	—	$40M
Q3 25	$14M	—	—	$42M

Revenue Segments

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$125M	$42M	$167M
Q1 23	$145M	$17M	$162M
Q2 23	$138M	$0	$138M
Q3 23	$115M	$0	$115M
Q4 23	$82M	$0	$82M
Q1 24	$227M	$0	$227M
Q2 24	$189M	$0	$189M
Q3 24	$145M	$0	$145M
Q4 24	$145M	$0	$145M
Q1 25	$115M	$0	$115M
Q2 25	$86M	$0	$86M
Q3 25	$92M	$0	$92M

Shares Outstanding

Revenue Per Employee

Revenue / Employee